eligibility_summary
Eligible: Age 14–69, R/R B‑cell lymphomas or HL with no options, CD20 and/or CD30+ (CD20+ after anti‑CD19 CAR‑T allowed), ECOG ≤2, ≥12‑wk survival, adequate apheresis access and organ function, EF ≥45%, SpO2>92%, nonpregnant, contraception. Exclude: active/untreated CNS disease, other cancers, major cardiac disease, uncontrolled infection (HBV/HCV/HIV), indwelling drains, active GVHD, autoimmune disease, recent prohibited drugs/RT/chemo/vaccines/DLI, recent VTE, marrow‑failure syndromes, poor compliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Autologous anti-CD20/CD30 CAR-T cells (genetically engineered T-cell therapy) given as a single IV infusion with 3+3 dose escalation after lymphodepleting fludarabine (purine analog antimetabolite) and cyclophosphamide (alkylating agent). Mechanisms: CAR-T cells are modified to recognize CD20 and/or CD30 on lymphoma cells, triggering MHC-independent T-cell activation and cytotoxic killing, fludarabine/cyclophosphamide deplete host lymphocytes to enhance CAR-T expansion and persistence. Targets: CD20+ malignant B cells (DLBCL, PMBCL, transformed FL, mantle cell, high-grade B-cell lymphoma, CLL/SLL) and CD30+ Hodgkin lymphoma (Reed–Sternberg cells). Focus: safety/early efficacy in relapsed/refractory lymphoma.